Pharmaco - Press Releases

Date	Title	Company
06-Jan-2022	Relief Reports US Collab. Partner announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies	RELIEF THERAPEUTICS Holding AG
05-Jan-2022	Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference	Sernova Corp.
05-Jan-2022	BIOCAPTIVA Provides Update and Remains on Track to Transform the Liquid Biopsy Market for Cancer Management	BIOCAPTIVA
05-Jan-2022	Covis Completes Acquisition of Global Respiratory Portfolio of Two Medicines from AstraZeneca	Covis Pharma Group
05-Jan-2022	OXURION to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference	OXURION
05-Jan-2022	Genmab and Synaffix Enter into License Agreement for ADC Technology	Genmab
05-Jan-2022	Thrombolytic Science Granted a Second US Patent on Its Clot Dissolving Therapy, A Novel, Nature-inspired Treatment for Ischemic Strokes	Thrombolytic Science, LLC
05-Jan-2022	Hansa Biopharma enters into agreement with AskBio to evaluate feasibility of imlifidase as pre-treatment ahead of gene therapy in Pompe disease	Hansa Biopharma
05-Jan-2022	AlzeCure presents novel Alzstatin data at the 11th Pharmaceutical Profiling meeting	AlzeCure
05-Jan-2022	Calibre Scientific Acquires AmpliTech, a French Distributor of Reagents and Instruments Specializing in Molecular Pathology, Cytogenetics, and Molecular Genetics	Calibre Scientific
05-Jan-2022	Santhera Enters into Exclusive License Agreement with Sperogenix for Vamorolone in Rare Diseases in the Greater China Region	Santhera
05-Jan-2022	Novo Holdings participates in EUR 110 million first closing of Sound Bioventures Fund I	Novo Holdings
05-Jan-2022	Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA	Oxurion NV
05-Jan-2022	Thrombolytic Science Granted a Second US Patent on Its Clot Dissolving Therapy, A Novel, Nature-inspired Treatment for Ischemic Strokes	B3C newswire
05-Jan-2022	Relief Therapeutics to Participate in Virtual Investor Conferences in January	RELIEF THERAPEUTICS Holding AG
04-Jan-2022	Optimization of mRNA containing nanoparticles	Technical University of Munich (TUM)
04-Jan-2022	Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use	RELIEF THERAPEUTICS Holding AG
04-Jan-2022	Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate in Upcoming Investor Conferences	Vivoryon Therapeutics N.V.
03-Jan-2022	Eckert & Ziegler Acquires Argentinian SPECT Specialist	Eckert & Ziegler Strahlen- und Medizintechnik AG
03-Jan-2022	Evotec receives € 7.5 m grant for development of COVID-19 therapeutic	Evotec SE